An Open-label Study of the Effect of First Line Treatment With Xeloda in Combination With Chemotherapy on Safety and Treatment Response in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-based Regimen.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety profile, specifically incidence of hand-foot syndrome
Throughout study
No
Clinical Trials
Study Director
Hoffmann-La Roche
Spain: Comite Etico de Investigacion Clinica
ML20777
NCT00454636
February 2007
May 2009
Name | Location |
---|